- Home
- BR vs RPRX Comparison
BR vs RPRX Comparison
Compare BR & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BR | RPRX |
|---|---|---|
| Founded | 1962 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.1B | 22.0B |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BR | RPRX |
|---|---|---|
| Price | $149.56 | $50.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $246.17 | $51.40 |
| AVG Volume (30 Days) | 1.1M | ★ 2.6M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.43% | 1.90% |
| EPS Growth | ★ 21.16 | N/A |
| EPS | ★ 6.18 | 0.67 |
| Revenue | ★ $4,142,600,000.00 | $2,378,193,000.00 |
| Revenue This Year | $10.04 | $38.63 |
| Revenue Next Year | $4.46 | $4.73 |
| P/E Ratio | ★ $24.59 | $74.33 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $149.05 | $32.15 |
| 52 Week High | $271.91 | $51.65 |
Technical Indicators
Market Signals| Indicator | BR | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 33.27 | 63.19 |
| Support Level | N/A | $35.35 |
| Resistance Level | $165.18 | N/A |
| Average True Range (ATR) | 4.66 | 0.97 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 6.62 | 61.01 |
Price Performance
Historical ComparisonAbout BR Broadridge Financial Solutions Inc.
Broadridge Financial Solutions, which was spun off from Automatic Data Processing in 2007, is a leading provider of investor communication and technology-driven solutions to banks, broker/dealers, traditional and alternative-asset managers, wealth managers, and corporate issuers. Broadridge is composed of two operating segments: investor communication solutions and global technology and operations.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.